Literature DB >> 7858328

Anticoagulation during continuous renal replacement therapy.

R L Mehta1.   

Abstract

Proper anticoagulation is an important factor in the function and life of the filter in CAVH or CAVHD and is the Achilles heel for CRRT. Several options now exist for anticoagulation and can be selected based on individual patient characteristics, availability of various anticoagulants, and local expertise. The choice of anticoagulant should be based on multiple factors, including A) the access site and whether an external pump is being used; B) the nature and geometry of the membrane; C) whether enhancements for ultrafiltration, such as predilution, are used; and D) the clinical status of the patient and preexisting coagulation abnormalities. Since anticoagulation in continuous therapy lasts longer than in intermittent hemodialysis, careful selection and monitoring are essential to prevent complications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858328

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

Review 1.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

2.  Ex vivo evaluation of a Taylor-Couette flow, immobilized heparinase I device for clinical application.

Authors:  G A Ameer; G Barabino; R Sasisekharan; W Harmon; C L Cooney; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 3.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

4.  Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Laura Zeppilli; Francesca Polistena; Emanuela Strampelli; Alessandro Pierucci
Journal:  Crit Care       Date:  2012-06-27       Impact factor: 9.097

5.  Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Elio Vitaliano; Laura Zeppilli; Francesca Polistena; Enrico Fiaccadori; Alessandro Pierucci
Journal:  BMC Nephrol       Date:  2013-10-25       Impact factor: 2.388

6.  Regional citrate anticoagulation in CVVH: a new protocol combining citrate solution with a phosphate-containing replacement fluid.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Laura Zeppilli; Francesca Polistena; Enrico Fiaccadori; Alessandro Pierucci
Journal:  Hemodial Int       Date:  2012-08-07       Impact factor: 1.812

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.